1,2-Dichloroethane → HCID 178458111, compound
Reaction equation
[NH:1]1[CH:5]=[C:4]([CH2:6][CH2:7][NH:8][C:9](=[O:24])[NH:10][CH:11]([CH2:15][C:16]2[CH:21]=[CH:20][C:19]([O:22][CH3:23])=[CH:18][CH:17]=2)[C:12]([OH:14])=O)[N:3]=[CH:2]1.[F:25][C:26]([F:31])([F:30])[C:27]([OH:29])=[O:28].[CH3:32][CH:33]1[CH2:38][CH2:37][CH2:36][CH2:35][CH:34]1[C:39]1([O:43][CH2:44][CH2:45][CH3:46])[CH2:42][NH:41][CH2:40]1.C(Cl)CCl.C1C=CC2N(O)N=NC=2C=1.[OH-].[Na+]>CN(C=O)C>[F:25][C:26]([F:31])([F:30])[C:27]([OH:29])=[O:28].[NH:1]1[CH:5]=[C:4]([CH2:6][CH2:7][NH:8][C:9]([NH:10][CH:11]([CH2:15][C:16]2[CH:21]=[CH:20][C:19]([O:22][CH3:23])=[CH:18][CH:17]=2)[C:12]([N:41]2[CH2:40][C:39]([CH:34]3[CH2:35][CH2:36][CH2:37][CH2:38][CH:33]3[CH3:32])([O:43][CH2:44][CH2:45][CH3:46])[CH2:42]2)=[O:14])=[O:24])[N:3]=[CH:2]1Participants
7
Procedure
To 97 mg (0.29 mmol) of 2-{3-[2-(1H-imidazol-4-yl)ethyl]ureido}-3-(4-methoxyphenyl)-propanoic acid (cf. preparation 2-3) dissolved in 2 mL of DMF are added 94 mg (0.29 mmol) of 3-(2-methylcyclohexyl)-3-propoxyazetidine trifluoroacetate, 70 mg (0.37 mmol) of EDC and 45 mg (0.33 mmol) of HOBt. After 3 hours, the reaction medium is hydrolysed with aqueous 1N sodium hydroxide solution and then extracted with dichloromethane. The organic phase is dried over MgSO4, filtered and concentrated. The crude product obtained is purified by preparative HPLC. 33 mg of 1-[2-(1H-imidazol-4-yl)ethyl]-3-{1-(4-methoxybenzyl)-2-[3-(2-methylcyclohexyl)-3-propoxyazetidin-1-yl]-2-oxoethyl}urea trifluoroacetate are obtained in a yield of 18%.
Workup
- extractionextracted with dichloromethane
- dry with materialThe organic phase is dried over MgSO4
- filtrationfiltered
- concentrationconcentrated
- customThe crude product obtained
- customis purified by preparative HPLC
Sources & evidence
- ORD record
- ord-c4b4663ad34a47b38f2e3982ddea94e3
- Source dataset
- uspto-grants-2014_11
- Patent number
- US08877968B2
Reaction notes
Loading…